Pimozide: Difference between revisions
| [unchecked revision] | [pending revision] |
MDElliottMD (talk | contribs) Auto-created stub |
MDElliottMD (talk | contribs) Category taxonomy (#23): retag to house-compliant neuroleptic categories |
||
| (7 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
{{MedTemplate | {{MedTemplate | ||
| generic | | generic = Pimozide | ||
| brand | | brand = Orap | ||
| classes | | structure = | ||
| mechanism | | classes = Antipsychotic, Neuroleptic | ||
| mechanism = Diphenylbutylpiperidine D2 antagonist | |||
| uses = | |||
| starting_dose = | |||
| preparations = | |||
| fda_max = | |||
| routes = | |||
| onset = | |||
| duration = | |||
| halflife = | |||
| bioavailability = | |||
| pregnancy = | |||
| legal = | |||
| intro = | |||
| pharmacokinetics = | |||
| pharmacodynamics = | |||
| indications = | |||
| dosing = | |||
| effects = | |||
| interactions = <pharmaInteractions/> | |||
| pregnancy_details = | |||
| monitoring = | |||
| counseling = | |||
| anecdotes = | |||
| seealso = | |||
| references = | |||
}} | }} | ||
[[Category:First-generation neuroleptics]] | |||
[[Category:Neuroleptics]] | [[Category:Neuroleptics]] | ||
[[Category:Diphenylbutylpiperidines]] | |||
Latest revision as of 14:41, 22 May 2026
Antipsychotic, Neuroleptic
Pimozide
Orap
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Interactions
Pharmacogenomic + mechanism interactions
Pharmacogenomic guideline recommendationsCPIC and Dutch Pharmacogenetics Working Group clinical guidelines
DPWG guideline: Patients who are CYP2D6 intermediate metabolizers should be given no more than 80% of the standard maximum dose of pimozide while patients who are CYP2D6 poor metabolizers should be given no more than 50% of the standard maximum dose.
Rate this interaction. Reports are anonymous and help curate the page.
Clinical relevance: does this interaction matter in practice?trivialcritical
Mechanism description, if it needs work:
Is this row worth surfacing?
Your own experience with this combination:
Experience (1 a little, 5 a lot)
Outcome (-100 worst, +100 best)
DPWG guideline: Patients who are CYP2D6 intermediate metabolizers should be given no more than 80% of the standard maximum dose of pimozide while patients who are CYP2D6 poor metabolizers should be given no more than 50% of the standard maximum dose.
Rate this interaction. Reports are anonymous and help curate the page.
Clinical relevance: does this interaction matter in practice?trivialcritical
Mechanism description, if it needs work:
Is this row worth surfacing?
Your own experience with this combination:
Experience (1 a little, 5 a lot)
Outcome (-100 worst, +100 best)
Patient experience
No patient-experience reports yet.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Classes
Antipsychotic, Neuroleptic
Common uses
Pharmacy
Pharmacology
Purported mechanism
Diphenylbutylpiperidine D2 antagonist